Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Asset Writedowns and Impairment (2016 - 2020)

Medifast (MED) has disclosed Asset Writedowns and Impairment for 7 consecutive years, with $48000.0 as the latest value for Q4 2020.

  • For the quarter ending Q4 2020, Asset Writedowns and Impairment fell 88.81% year-over-year to $48000.0, compared with a TTM value of $7.0 million through Dec 2020, up 0.69%, and an annual FY2020 reading of $556000.0, down 84.72% over the prior year.
  • Asset Writedowns and Impairment was $48000.0 for Q4 2020 at Medifast, down from $429000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $6.1 million in Q2 2016 and bottomed at $48000.0 in Q4 2020.
  • Average Asset Writedowns and Impairment over 5 years is $2.6 million, with a median of $429000.0 recorded in 2019.
  • The sharpest move saw Asset Writedowns and Impairment rose 3.12% in 2019, then crashed 88.81% in 2020.
  • Year by year, Asset Writedowns and Impairment stood at $6.1 million in 2016, then changed by 0.0% to $6.1 million in 2017, then plummeted by 93.18% to $416000.0 in 2018, then grew by 3.12% to $429000.0 in 2019, then plummeted by 88.81% to $48000.0 in 2020.
  • Business Quant data shows Asset Writedowns and Impairment for MED at $48000.0 in Q4 2020, $429000.0 in Q4 2019, and $416000.0 in Q4 2018.